Ascendis Pharma A/S (ASND) Raised to “Strong-Buy” at ValuEngine

ValuEngine upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a buy rating to a strong-buy rating in a research note published on Wednesday.

Several other analysts have also issued reports on the company. Credit Suisse Group increased their price objective on Ascendis Pharma A/S from $80.00 to $86.00 and gave the stock an outperform rating in a report on Thursday, November 29th. Zacks Investment Research lowered Ascendis Pharma A/S from a buy rating to a hold rating in a report on Tuesday, November 13th. BidaskClub upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a report on Friday, October 19th. Wedbush set a $79.00 price objective on Ascendis Pharma A/S and gave the stock a buy rating in a report on Thursday, August 30th. Finally, JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $79.00 to $81.00 and gave the stock an overweight rating in a report on Thursday, August 30th. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $77.56.

Shares of NASDAQ:ASND opened at $64.71 on Wednesday. Ascendis Pharma A/S has a 1 year low of $36.07 and a 1 year high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, November 28th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.23) by $0.29. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.16 million. Analysts anticipate that Ascendis Pharma A/S will post -4.01 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC raised its holdings in Ascendis Pharma A/S by 31.1% during the second quarter. Orbimed Advisors LLC now owns 4,413,291 shares of the biotechnology company’s stock valued at $293,572,000 after buying an additional 1,045,976 shares in the last quarter. FMR LLC raised its holdings in Ascendis Pharma A/S by 24.3% during the third quarter. FMR LLC now owns 4,152,262 shares of the biotechnology company’s stock valued at $294,230,000 after buying an additional 812,468 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Ascendis Pharma A/S by 2.7% during the third quarter. Alliancebernstein L.P. now owns 714,366 shares of the biotechnology company’s stock valued at $50,620,000 after buying an additional 19,039 shares in the last quarter. Marshall Wace North America L.P. raised its holdings in Ascendis Pharma A/S by 9.9% during the third quarter. Marshall Wace North America L.P. now owns 703,087 shares of the biotechnology company’s stock valued at $49,821,000 after buying an additional 63,540 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Ascendis Pharma A/S by 7.8% during the third quarter. Franklin Resources Inc. now owns 591,898 shares of the biotechnology company’s stock valued at $41,942,000 after buying an additional 42,800 shares in the last quarter. Institutional investors own 95.60% of the company’s stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: Penny Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply